Partial
Partially Aligned
Patient Risk:
Moderate
Summary
The only directly label-verifiable component provided is an indication statement, which appears consistent with the supplied label excerpt; however, the AI response does not actually evaluate the full, concrete AI-generated drug label content and relies on unverifiable assertions about alignment across other sections.
Category Scores
Accurate Statements
ONUREG is indicated for continued treatment of adult patients with acute myeloid leukemia who achieved first complete remission (CR) or complete remission with incomplete blood count recovery (CRi) following intensive induction chemotherapy and are not able to complete intensive curative therapy.
Supported by FDA label excerpt in 1 INDICATIONS AND USAGE.
Unsupported Statements
The response asserts that the claim is aligned with FDA-labeled indication for ONUREG and that it is distinguished from IV/SC azacitidine in sections 2.1 and 5.1, supporting correct product/usage alignment; and that contradicted: no.
The prompt’s provided AI evaluation discusses multiple label sections and overall adherence, but does not include the specific AI-generated indication claim text to verify against those sections. Therefore, cross-section alignment beyond Section 1 cannot be confirmed from the supplied input.
The response asserts absent_from_label_sections is empty for the evaluated claim.
No concrete, fully specified evaluated claim text (beyond a general indication) is provided for verification; therefore absence/presence of other required labeling elements cannot be reliably concluded.
Contradictions
Important Omissions
Verification that the evaluated AI response content matches other material labeling elements (e.g., contraindications, warnings/precautions including myelosuppression and substitution risks, adverse reactions, drug interactions, and pediatric use) is not performed because the prompt only provides label excerpts and does not provide the full AI-generated response content being evaluated.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
Because the AI response claims broad on-label alignment while only the indication excerpt is clearly verifiable from the provided label text, potential risk arises from incomplete confirmation of key safety-related label elements.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Partially Aligned
Primary Issue
Overconfident claims of overall label alignment ('supported: yes', 'contradicted: no') are not verifiable beyond the indication section with the provided inputs.
Suggested Improvement
Evaluate and cite the exact AI-generated statements against the relevant label sections (1, 2.1, 4, 5, 6, 8, etc.) using explicit statement-by-statement mapping; avoid concluding full on-label alignment when only the indication text can be confirmed.